VFVanda Faria

Vanda Faria

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vanda Faria has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Authors’ reply to Steiner et al.: “Migraine and headache in children and adolescents: a 2026 evidence-based factsheet”

    by Derya Uludüz, Vanda Faria, Ishaq Abu-Arafeh, Serena Laura Orr, Toshiyuki Hikita, Hamit Genç, Aynur Özge

  • Open Access

    Migraine and headache in children and adolescents: A 2026 evidence-based factsheet

    by Derya Uludüz, Ishaq Abu-Arafeh, Serena Laura Orr, Nazia Karsan, Vanda Faria, Nana Nino Tatishvili, Marco Lisicki, Toshiyuki Hikita, Hamit Genç, Aynur Özge

    Background: Headache disorders, particularly migraine, are among the leading causes of disability worldwide, with onset frequently occurring during childhood and adolescence. Despite their high prevalence and substantial functional impact, paediatric headache disorders remain under-recognised within health systems and under-represented in global policy frameworks. Methods: This factsheet was developed to provide a comprehensive, developmentally informed overview of the global burden of headache disorders in children and adolescents. It synthesises evidence from population-based studies, systematic reviews, clinical cohorts, and Global Burden of Disease (GBD) 2023 estimates. Key domains include epidemiology, disability burden, functional and psychosocial impacts, risk factors and triggers, diagnostic and treatment gaps, and current management strategies, with particular attention to disparities across sociodemographic groups. Results: According to GBD 2023 point-prevalence estimates, headache disorders increase markedly across development, from 10.71% among children aged 5–9 years to 42.64% among adolescents aged 15–19 years. Corresponding migraine prevalence estimates increase from 2.79% to 18.08%. GBD 2023 data also indicate that migraine is among the leading causes of years lived with disability from early life onwards.Migraine in children and adolescents is associated with substantial impairment in school attendance, academic performance, social participation, and quality of life. It is also frequently accompanied by psychiatric and somatic comorbidities. Access to timely diagnosis and evidence-based treatment remains highly inequitable, particularly in low- and middle-income countries. Emerging evidence suggests that adolescence may represent a critical window for intervention, with the potential to reduce progression to chronic migraine and long-term disability. Conclusions: Migraine and other headache disorders in children and adolescents constitute a major global public health challenge. This factsheet provides a comprehensive, evidence-based summary of their burden and highlights urgent priorities for policy integration, advocacy, and research. Early, equitable, and developmentally tailored care is essential to reduce lifelong disability and improve global brain health outcomes.


  • Open Access

    Editorial: Optimizing the therapeutic potential in clinical settings: leveraging placebos and mitigating nocebo effects

    by Vanda Faria, Michael Bernstein, Marco Annoni, Tomas Furmark, Eric A. Moulton

    The Opinion ar cle by Poulter et al. (1) provides an important conceptual anchor for this Topic by addressing misunderstandings surrounding contextual effects in musculoskeletal pain. The authors highlight four key sources of tension between clinicians and researchers: terminology, clinical relevance, beliefs and expecta ons, and sta s cal es ma on methods. They argue that contextual factors are components of all therapeu c encounters, and call for clearer defini ons, improved repor ng prac ces, and construc ve interdisciplinary dialogue. Their reflec ons suggest that these phenomena should not be viewed as unusual problems to eliminate, but as integral elements of clinical care that require though ul integra on and rigorous inves ga on. This conceptual groundwork sets the stage for the empirical contribu ons that follow.A central transla onal focus of this research topic concerns open-label placebos (OLPs), which aim to harness placebo effects while maintaining transparency. Paschke-Dahl and Klinger (2) inves gated OLPs in fibromyalgia pa ents undergoing gluten challenge in a 2×2 design (gluten vs. sham gluten; neutral vs. posi ve OLP instruc ons). Posi ve OPL instruc ons were associated with decreases in pain over me, while neutral OPL instruc ons were associated with increases. Gluten itself showed no significant effect on pain or indiges on, and a strong correla on was observed between expected and actual pain relief. These findings highlight the relevance of expecta on-related processes in symptom modula on within this context. Two secondary analyses further suggest that responsiveness to OLPs may depend on the psychological profile of par cipants individual characteris cs. Frisaldi et al. (3) report that in medical students, OLP intake (compared to no interven on) was associated with improved test performance among those with higher test anxiety and among students adop ng beneficial learning strategies. Similarly, Caliskan et al. (4) found that in chronic low back pain pa ents, lower baseline pain catastrophizing predicted objec ve improvement in spinal mo on velocity in the OLP plus treatment-as-usual group, whereas those with higher catastrophizing did not show this benefit. Together, these studies underscore the importance of examining psychological moderators when considering OLP implementa on. Complemen ng these findings, Nascimento et al. (5) explored pa ents' a tudes toward OLP implementa on through qualita ve focus groups involving individuals with chronic back pain, chronic migraine, or chemotherapy-induced nausea/emesis. Iden fied themes reflected both interest and ambivalence of using OLPs. To the extent pa ents were willing to consider OLPs trust and clinician credibility were prerequisites. These findings suggest that successful clinical transla on depends not only on demonstra ng efficacy, but also on how OLPs are communicated and embedded within therapeu c rela onships, consist with prior work on the importance of perceived warmth and competence from a healthcare provider (6).Just as posi ve expecta ons can enhance outcomes, nega ve expecta ons can amplify adverse experiences. Addressing this challenge, Asan et al. (7) present a preregistered, double-blind randomized controlled clinical trial protocol designed to test whether op mized communica on during informed consent for lumbar puncture can reduce headache-related impairment compared to standard communica on. The protocol is mo vated by evidence that risk disclosure can increase reports of side effects by enhancing nega ve expecta ons. Importantly, the study aims to mi gate poten al nocebo-associated effects without withholding informa on cri cal to pa ents, thereby aligning ethical transparency with symptom preven on. This contribu on exemplifies the prac cal and ethical complexi es at the heart of placebo and nocebo transla on: improving outcomes while preserving pa ent autonomy and trust.Clinical applica on of placebos also unfolds within legal and regulatory frameworks. Richard et al. in "A Dose of Doubt" report qualita ve findings from Swiss primary care physicians, who described using impure placebos in prac ce and emphasized risk-benefit evalua on as a primary jus fica on (8). Knowledge of regula ons varied, and par cipants generally did not perceive a strong need for addi onal formal regula on. In a complementary legal analysis in "Noble Humbug?", Richard et al. examined binding and non-binding laws across France, Germany, Switzerland, the UK, and the USA (9). They report that placebo use is o en indirectly regulated through informed consent statutes rather than placebo-specific legisla on, and that professional guidelines, such as those from the American Medical Associa on, outline condi ons under which placebo use may be permissible. The authors emphasize that unauthorized placebo use may carry legal implica ons, highligh ng the importance of clear standards and transparent communica on. The emergence of OLP is discussed as a development with poten al to address ethical tensions while preserving clinical flexibility.The importance of therapeu c context is further reflected in the retrospec ve study by Vora et al (10), examining outcomes of an interdisciplinary func onal restora on program for adults with highimpact chronic pain and clinically elevated catastrophizing. Par cipants demonstrated sta s cally significant improvements in func onal performance, sa sfac on with func on, pain ra ngs, mood, and catastrophizing following program comple on. The authors describe the program's emphasis on collabora on, valida on, trust, self-efficacy, and posi ve expecta ons. These findings align with broader themes in this Topic regarding the clinical relevance of enriched therapeu c encounters.The Perspec ve by Furmark et al. (11) revisits debates surrounding SSRI and placebo effects in social anxiety disorder. The authors report findings from neuroimaging studies in which SSRI and placebo responders...

  • Open Access

    Investigating Placebos and Controls Used in Large Language Model–Based Chatbot Intervention Trials: Protocol for a Methodological Review

    by Leo Druart, Vanda Faria, Marco Annoni, John Torous, Moa Pontén, Charlotte Blease

    Background: Large language model (LLM)–based chatbots are rapidly being repurposed as patient-facing digital health tools. Their interactive, adaptive, and seemingly empathic behavior can heighten engagement and expectancy—nonspecific factors that complicate causal inference. Yet, comparator strategies in LLM trials are inconsistently defined and often undermatched (eg, minimal education vs highly engaging chatbots), risking biased effect estimates and poor reproducibility. Objective: The aim of this study was to systematically identify and categorize the control conditions used in interventional studies of LLM-based, patient-facing digital health interventions and to evaluate their methodological appropriateness. Secondary aims are to describe variability by health domain and study design and to explore whether control type/quality relates to the direction of reported effects. Methods: This protocol follows PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) and is registered in PROSPERO. Eligible studies are interventional designs that evaluate LLM-based, patient-facing digital health interventions; any control condition is eligible (including no control, waitlist, treatment-as-usual, attention/education, active comparator, or sham digital control). We will search PubMed, PsycINFO, CENTRAL, CINAHL, and Scopus for records from January 1, 2023, onward. All records will be managed and screened in Rayyan by 2 independent reviewers. Dual, independent data extraction will target study context, intervention details, and control-arm characteristics (typology, rationale, matching to nonspecifics, blinding, reporting). No formal risk-of-bias assessments are planned, as the focus is on meta-research. Results: At submission, the protocol is registered in PROSPERO and has received no specific funding. Scoping searches are complete; full screening and extraction have not yet commenced. Conclusions: This review will provide an empirical map of control practices in LLM chatbot trials and guidance for designing better-matched comparators, supporting more valid and interpretable evaluations as LLMs diffuse into patient care. Trial Registration: PROSPERO CRD420251246148; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251246148 International Registered Report Identifier (IRRID): PRR1-10.2196/90507

  • Open Access

    Investigating Placebos and Controls Used in Large Language Model–Based Chatbot Intervention Trials: Protocol for a Methodological Review (Preprint)

    by Leo Druart, Vanda Faria, Marco Annoni, John Torous, Moa Pontén, Charlotte Blease

    BACKGROUND Large language model (LLM)–based chatbots are rapidly being repurposed as patient-facing digital health tools. Their interactive, adaptive, and seemingly empathic behavior can heighten engagement and expectancy—nonspecific factors that complicate causal inference. Yet, comparator strategies in LLM trials are inconsistently defined and often undermatched (eg, minimal education vs highly engaging chatbots), risking biased effect estimates and poor reproducibility. OBJECTIVE The aim of this study was to systematically identify and categorize the control conditions used in interventional studies of LLM-based, patient-facing digital health interventions and to evaluate their methodological appropriateness. Secondary aims are to describe variability by health domain and study design and to explore whether control type/quality relates to the direction of reported effects. METHODS This protocol follows PRISMA-P (Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols) and is registered in PROSPERO. Eligible studies are interventional designs that evaluate LLM-based, patient-facing digital health interventions; any control condition is eligible (including no control, waitlist, treatment-as-usual, attention/education, active comparator, or sham digital control). We will search PubMed, PsycINFO, CENTRAL, CINAHL, and Scopus for records from January 1, 2023, onward. All records will be managed and screened in Rayyan by 2 independent reviewers. Dual, independent data extraction will target study context, intervention details, and control-arm characteristics (typology, rationale, matching to nonspecifics, blinding, reporting). No formal risk-of-bias assessments are planned, as the focus is on meta-research. RESULTS At submission, the protocol is registered in PROSPERO and has received no specific funding. Scoping searches are complete; full screening and extraction have not yet commenced. CONCLUSIONS This review will provide an empirical map of control practices in LLM chatbot trials and guidance for designing better-matched comparators, supporting more valid and interpretable evaluations as LLMs diffuse into patient care. CLINICALTRIAL PROSPERO CRD420251246148; https://www.crd.york.ac.uk/PROSPERO/view/CRD420251246148 INTERNATIONAL REGISTERED REPORT PRR1-10.2196/90507

  • Open Access

    Triadic relations in healthcare: surveying physicians’ perspectives on generative AI integration and its role on empathy, the placebo effect and patient care

    by Vanda Faria, Nathan Goturi, Amanda Dynak, Cameron Talbert, Nicholas Pondelis, Marco Annoni, Charlotte Blease, Scott A. Holmes, Eric A. Moulton

    Background: The integration of generative artificial intelligence (genAI) tools into clinical practice and health care systems is reshaping modern healthcare, introducing technology as an active third participant in the evolving physician–patient–technology relationship. As these tools begin to play more prominent roles, understanding physicians’ perspectives is essential for guiding their ethical and effective use. Objective: This survey examined physicians’ use of genAI and their views on its potential impact on empathy, the physician–patient relationship, and psychobiological mechanisms such as the placebo and nocebo effects. Methods: A cross-sectional survey was distributed to 2,444 physicians at a major academic pediatric hospital in Boston (October 2024–February 2025). The survey included items on genAI use, perceptions of its clinical and relational impact, and associated concerns. A total of 319 (13%) completed responses were analyzed using descriptive and inferential statistics. Results: Within 2 years of the public release, 65.2% of respondents had used genAI tools, most commonly for administrative tasks like writing emails (55.8%) and documentation (31.3%). Use was more common among younger physicians and men. A majority believed genAI could improve patient care (60.7%) and increase time for direct interaction (65.7%). However, views were more divided regarding its ability to support empathetic care or influence placebo effects, with many physicians expressing neutrality or uncertainty. Notably, 50.8% agreed that genAI-human interactions could increase patient anxiety, indicating concern about potential nocebo effects. Perspectives on broader genAI adoption were mixed, with 30.6% expressing concern and 37.7% neutral. Conclusion: Physicians are rapidly adopting genAI tools, primarily for administrative use, while remaining cautious about its relational and psychological implications. These findings underscore the importance of addressing ethical concerns and supporting clinicians as they navigate this evolving triadic relationship between physician, patient, and genAI.


  • Open Access

    Eyelid heat pain sensitivity in healthy participants

    by Nicholas J. Pondelis, Vanda Faria, Hailey Krasnikov, Cameron Talbert, Madison Dudek, Paula A. Sepulveda-Beltran, David Valdes-Arias, David Zurakowski, Anat Galor, Scott Holmes, et al.

    Introduction: Chronic ocular pain (COP) is a widespread pain condition that presents clinical challenges, has heterologous and overlapping etiologies across patients, and can have a debilitating effect on quality of life. It can manifest with neuropathic-like symptoms as well as dysesthesias associated with afferent disruption, brain dysfunction, or both, complicating diagnosis and treatment. Quantitative sensory testing (QST) has been used extensively in individuals with chronic pain to detect abnormal peripheral and central nervous system function. Investigating relevant sensory thresholds is crucial for integrating QST into ocular pain assessments. Objectives: This study aimed to determine heat pain thresholds on the eyelid in healthy participants. Furthermore, we sought to evaluate the eyelid as a feasible and suitable body site for COP investigation using QST. Methods: Heat pain thresholds were measured in 80 healthy participants at 2 study sites using the method of limits at 3 stimulation sites: the upper eyelid, the forehead, and the volar forearm. Results: Analysis revealed a significantly lower estimated marginal mean (EMM) heat pain threshold on the eyelid (42.5 ± 0.4 EMM ± SE) compared with the forehead (46.6 ± 0.4 EMM ± SE) (P < 0.001) and forearm (46.4 ± 0.4 EMM ± SE) (P < 0.001). These differences were statistically significant regardless of sex, study site, or age. No differences were found between the forehead and the forearm (P = 1.00). Conclusion: The eyelid is a clinically relevant site for QST in the investigation of ocular and trigeminal function, and this study sets the groundwork for applying eyelid QST in future research of ocular pain and disease etiology.


  • Open Access

    Impact of a 12-week olfactory training programme in women with migraine with aura: protocol for a double-blind, randomised, placebo-controlled trial

    by Vanda Faria, Jana Dulheuer, Akshita Joshi, Hannes Wahl, Anna Klimova, Antje Haehner, Gudrun Gossrau

    Introduction Migraine is a leading cause of disability and suffering worldwide. However, conventional pharmacological migraine preventive therapies are often challenging and accompanied by adverse effects. Recently, structured odour exposure has shown to successfully increase pain thresholds in patients with chronic back pain. Despite the importance of the olfactory system in migraine, there are no studies investigating the impact of structured odour exposure in patients with migraine. Methods and analysis This double-blind randomised placebo-controlled trial will be conducted at the Headache Clinic of the University Pain Center at TU Dresden, Germany and aims at investigating the impact of a 12-week structured exposure to odours in women with migraine. Fifty-four women between 18 and 55 years with migraine with aura will be recruited and randomised to training with odours and odourless training. The primary outcomes are mechanical and electrical pain thresholds. Secondary outcomes comprise olfactory threshold and the number of headache days. Other exploratory measurements are headache associated pain intensity, acute analgesic intake, symptoms of anxiety and depression, and quality of life. Additionally, this protocol assesses neuroanatomical and neurofunctional changes associated with the 12-week olfactory training. Data analysis will be executed on the basis of the general linear model considering repeated measurements. Ethics and dissemination Ethical approvals were obtained from the Ethics Board of the TU Dresden (Protocol No. BO-EK-353082020). Participation will only be possible after written informed consent is provided. Findings will be disseminated through peer-reviewed journals and scientific conferences. Trial registration number DRKS00027399.


  • Open Access

    Placebos in pediatrics: A cross-sectional survey investigating physicians' perspectives

    by Vanda Faria, Cameron Talbert, Nathan Goturi, David Borsook, Alyssa Lebel, Ted J. Kaptchuk, Irving Kirsch, John M. Kelley, Eric A. Moulton


  • Open Access

    Dorsal anterior cingulate cortex activity during cognitive challenge in social anxiety disorder

    by Magdalena Wlad, Andreas Frick, Jonas Engman, Olof Hjorth, Johanna M. Hoppe, Vanda Faria, Kurt Wahlstedt, Johannes Björkstrand, Kristoffer Nt Månsson, Sara Hultberg, et al.